RareCyte Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 64

Employees

  • Latest Deal Type
  • Debt

  • Investors
  • 11

RareCyte General Information

Description

Developer of precision biology products intended to detect circulating tumor cells. The company designs, manufactures, and markets worldwide end-to-end integrated platforms that provide advances in discovery, translational, and future clinical markets, enabling medical researchers to monitor circulating tumor cell counts and biomarker expression over time for clinical research.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2601 Fourth Avenue
  • Suite 500
  • Seattle, WA 98121
  • United States
+1 (855)
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2601 Fourth Avenue
  • Suite 500
  • Seattle, WA 98121
  • United States
+1 (855)

RareCyte Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RareCyte Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Debt - General 01-Apr-2026 Completed Generating Revenue
12. Grant 21-Aug-2025 Completed Generating Revenue
11. Later Stage VC 21-Nov-2024 Completed Generating Revenue
10. Later Stage VC (Series H) 25-Jul-2023 Completed Generating Revenue
9. Later Stage VC (Series G) 09-Sep-2021 Completed Generating Revenue
8. Debt - PPP 13-Apr-2020 Completed Generating Revenue
7. Later Stage VC (Series F) 19-Dec-2019 Completed Generating Revenue
6. Debt - General 06-Jul-2018 Completed Generating Revenue
5. Later Stage VC (Series E) 22-May-2018 $5M $53M Completed Generating Revenue
4. Later Stage VC (Series D) 26-Jul-2017 $16M $48M Completed Generating Revenue
To view RareCyte’s complete valuation and funding history, request access »

RareCyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series H
Series G
Series F
Series E
Series D
Series C
Series B 1,500,000 $0.000010 $2.5 $2.5 1x $2.5 0.41%
Series A 3,200,000 $0.000010 $1.64 $1.64 1x $1.64 0.88%
To view RareCyte’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

RareCyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of precision biology products intended to detect circulating tumor cells. The company designs, manufactures, a
Diagnostic Equipment
Seattle, WA
64 As of 2025

Heidelberg, Germany
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

RareCyte Competitors (39)

One of RareCyte’s 39 competitors is Epigenomics, a Formerly VC-backed company based in Heidelberg, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Epigenomics Formerly VC-backed Heidelberg, Germany
Foundation Medicine Formerly VC-backed Boston, MA
Exosomics Venture Capital-Backed Siena, Italy
ROCA Test Formerly VC-backed Cambridge, United Kingdom
Viatar CTC Solutions Formerly VC-backed Lowell, MA
You’re viewing 5 of 39 competitors. Get the full list »

RareCyte Patents

RareCyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260072261-A1 Transmitted light microscopy systems and methods of use Pending 06-Sep-2024
US-12038381-B1 Methods of reducing spectral crosstalk in multiplexed fluorescence imaging Active 18-Aug-2023
WO-2025042409-A1 Methods of reducing spectral crosstalk in multiplexed fluorescence imaging Inactive 18-Aug-2023
AU-2020440916-A1 Optical trains for imaging systems and spectral edge detection Pending 06-Apr-2020
CA-3174791-A1 Optical trains for imaging systems and spectral edge detection Pending 06-Apr-2020 G02B21/16
To view RareCyte’s complete patent history, request access »

RareCyte Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RareCyte Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gates Foundation Not-For-Profit Venture Capital
GKCC Venture Capital Minority
Sheatree Capital Venture Capital Minority
The Forest Road Company VC-Backed Company Minority
Agilent Technologies Corporation Minority
You’re viewing 5 of 11 investors. Get the full list »

RareCyte FAQs

  • When was RareCyte founded?

    RareCyte was founded in 2009.

  • Where is RareCyte headquartered?

    RareCyte is headquartered in Seattle, WA.

  • What is the size of RareCyte?

    RareCyte has 64 total employees.

  • What industry is RareCyte in?

    RareCyte’s primary industry is Diagnostic Equipment.

  • Is RareCyte a private or public company?

    RareCyte is a Private company.

  • What is RareCyte’s current revenue?

    The current revenue for RareCyte is .

  • How much funding has RareCyte raised over time?

    RareCyte has raised $130M.

  • Who are RareCyte’s investors?

    Gates Foundation, GKCC, Sheatree Capital, The Forest Road Company, and Agilent Technologies are 5 of 11 investors who have invested in RareCyte.

  • Who are RareCyte’s competitors?

    Epigenomics, Foundation Medicine, Exosomics, ROCA Test, and Viatar CTC Solutions are some of the 39 competitors of RareCyte.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process